ChartWise appoints Steven Mason as president, COO

ChartWise Medical Systems,providers of computer-assisted clinical documentation improvement (CACDI) software, has announced Steven Mason as its president and COO.

“The company is well-regarded within the industry and has been recognized as a KLAS CDI category winner three years in a row for continuously raising the bar and advancing the technology hospitals and medical centers rely on for accurate coding, documentation and reimbursement,” said Mason. "I look forward to hitting the ground running as we take ChartWise to the next level of growth and product leadership.”

Company founder Jon Elion will remain CEO while Mason focuses on consumer growth and satisfaction. Mason comes to ChartWise after holding the senior vice president and GM positions at Enterprise Performance Management Solutions, where he managed the Mede Performance Management (MedePM) business unit. Additionally, Mason was the co-founder and CEO of the recently acquired OnFocus Healthcare by MedeAnalytics.

“We’ve known and worked with Steven for several years and now is the perfect time to bring him into the fold,” said Elion. “Steven’s strategic expertise in facilitating accelerated growth with healthcare technology companies is an excellent fit with the proven track record that ChartWise has established in product innovation.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.